↓ Skip to main content

Dove Medical Press

Birdshot uveitis: current and emerging treatment options

Overview of attention for article published in Clinical Ophthalmology, December 2013
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

twitter
3 X users
facebook
3 Facebook pages

Citations

dimensions_citation
27 Dimensions

Readers on

mendeley
46 Mendeley
Title
Birdshot uveitis: current and emerging treatment options
Published in
Clinical Ophthalmology, December 2013
DOI 10.2147/opth.s54832
Pubmed ID
Authors

Victor Menezo, Simon RJ Taylor

Abstract

Birdshot chorioretinopathy is a relatively uncommon subtype of idiopathic posterior uveitis with distinct clinical characteristics and a strong genetic association with the Human Leukocyte Antigen (HLA)-A29 allele. The diagnosis remains clinical and is based on the presence of typical clinical features, including multiple, distinctive, hypopigmented choroidal lesions throughout the fundus. The long-term visual prognosis of this disorder, however, remains guarded - central visual acuity can be preserved until late in the disease and it is not uncommon for patients to receive inadequate immunosuppressive treatment, leading to a poor long-term outcome in which peripheral retinal damage eventually leads to visual deterioration. Birdshot chorioretinopathy has proven a particularly attractive area of study within the field of uveitis, as it is a relatively easily defined disease with an associated human leukocyte antigen haplotype. Despite this, however, the immune mechanisms involved in its pathogenesis remain unclear, and some patients continue to lose retinal function despite therapy with corticosteroids and conventional immunosuppressive agents. Laboratory research continues to investigate the underlying mechanisms of disease, and clinical research is now being driven to improve the phenotyping and monitoring of this condition as, in the era of so-called personalized medicine, it is becoming increasingly important to identify patients at risk of visual loss early so that they can be treated more aggressively with targeted therapies such as the newer biological agents. This approach requires the formation of collaborative groups, as the relative rarity of the condition makes it difficult for one center to accumulate enough patients for worthwhile studies. Nevertheless, results obtained with newer therapies, such as biological agents directed against particular cytokines or cell-surface receptors, demonstrate ever improving control of the inflammation in refractory cases, providing hope that the outlook for visual function in this condition can only improve.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 1 2%
Unknown 45 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 7 15%
Researcher 5 11%
Student > Doctoral Student 4 9%
Student > Bachelor 4 9%
Student > Master 4 9%
Other 8 17%
Unknown 14 30%
Readers by discipline Count As %
Medicine and Dentistry 19 41%
Agricultural and Biological Sciences 4 9%
Social Sciences 2 4%
Biochemistry, Genetics and Molecular Biology 2 4%
Pharmacology, Toxicology and Pharmaceutical Science 1 2%
Other 2 4%
Unknown 16 35%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 January 2014.
All research outputs
#14,519,165
of 25,584,565 outputs
Outputs from Clinical Ophthalmology
#1,000
of 3,687 outputs
Outputs of similar age
#172,522
of 321,951 outputs
Outputs of similar age from Clinical Ophthalmology
#13
of 62 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,687 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.0. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 321,951 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 62 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.